Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients
AbstractSphingolipids are characterized by a broad range of bioactive properties. Particularly, the development of insulin resistance, a major pathophysiological hallmark of Type 2 Diabetes mellitus (T2D), has been linked to ceramide signaling. Since vitamin D supplementation may slow down T2D progression by improving glucose concentrations and insulin sensitivity, we investigated whether vitamin D supplementation impacts on plasma sphingolipid levels in T2D patients. Thus, plasma samples of 59 patients with non-insulin-requiring T2D from a placebo-controlled, randomized, and double-blind study were retrospectively analyzed. Once per week, patients received either 20 drops of Vigantol oil, corresponding to a daily dose of 1904 IU/d vitamin D (verum: n = 31), or a placebo oil consisting of medium chain triglycerides (placebo: n = 28). Blood samples were taken from all of the participants at three different time points: 1) at the beginning of the study (baseline), 2) after 6 months supplementation, and 3) after an additional 6 months of follow-up. Plasma sphingolipids were measured by high-performance liquid chromatography tandem mass spectrometry. At baseline and 6 months follow-up, no significant differences in plasma sphingolipid species were detected between the placebo and verum groups. After 6 months, vitamin D supplementation significantly enhanced plasma C18dihydroceramide (dhCer; N-stearoyl-sphinganine (d18:0/18:0)) and C18ceramide (Cer; N-stearoyl-sphingosine (d18:1/18:0)) levels were observed in the verum group compared to the placebo group. This was accompanied by significantly higher 25-hydroxyvitamin D3 (25(OH)D3) blood levels in patients receiving vitamin D compared to the placebo group. Taken together, vitamin D supplementation induced changes of the C18 chain-length-specific dhCer and Cer plasma levels in patients with T2D. The regulation of sphingolipid signaling by vitamin D may thus unravel a novel mechanism by which vitamin D can influence glucose utilization and insulin action. Whether this acts favorably or unfavorably for the progression of T2D needs to be clarified. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 162 KB)
Share & Cite This Article
Koch, A.; Grammatikos, G.; Trautmann, S.; Schreiber, Y.; Thomas, D.; Bruns, F.; Pfeilschifter, J.; Badenhoop, K.; Penna-Martinez, M. Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients. Int. J. Mol. Sci. 2017, 18, 1532.
Koch A, Grammatikos G, Trautmann S, Schreiber Y, Thomas D, Bruns F, Pfeilschifter J, Badenhoop K, Penna-Martinez M. Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients. International Journal of Molecular Sciences. 2017; 18(7):1532.Chicago/Turabian Style
Koch, Alexander; Grammatikos, Georgios; Trautmann, Sandra; Schreiber, Yannick; Thomas, Dominique; Bruns, Franziska; Pfeilschifter, Josef; Badenhoop, Klaus; Penna-Martinez, Marissa. 2017. "Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients." Int. J. Mol. Sci. 18, no. 7: 1532.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.